271 related articles for article (PubMed ID: 28400128)
1. HTA programme response to the challenges of dealing with orphan medicinal products: Process evaluation in selected European countries.
Nicod E; Annemans L; Bucsics A; Lee A; Upadhyaya S; Facey K
Health Policy; 2019 Feb; 123(2):140-151. PubMed ID: 28400128
[TBL] [Abstract][Full Text] [Related]
2. Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries.
Nicod E
Eur J Health Econ; 2017 Jul; 18(6):715-730. PubMed ID: 27538758
[TBL] [Abstract][Full Text] [Related]
3. Dealing with Uncertainty and Accounting for Social Value Judgments in Assessments of Orphan Drugs: Evidence from Four European Countries.
Nicod E; Berg Brigham K; Durand-Zaleski I; Kanavos P
Value Health; 2017; 20(7):919-926. PubMed ID: 28712621
[TBL] [Abstract][Full Text] [Related]
4. Reconciling uncertainty of costs and outcomes with the need for access to orphan medicinal products: a comparative study of managed entry agreements across seven European countries.
Morel T; Arickx F; Befrits G; Siviero P; van der Meijden C; Xoxi E; Simoens S
Orphanet J Rare Dis; 2013 Dec; 8():198. PubMed ID: 24365263
[TBL] [Abstract][Full Text] [Related]
5. SCIENTIFIC AND SOCIAL VALUE JUDGMENTS FOR ORPHAN DRUGS IN HEALTH TECHNOLOGY ASSESSMENT.
Nicod E; Kanavos P
Int J Technol Assess Health Care; 2016 Jan; 32(4):218-232. PubMed ID: 27624559
[TBL] [Abstract][Full Text] [Related]
6. Systematic review on the evaluation criteria of orphan medicines in Central and Eastern European countries.
Zelei T; Molnár MJ; Szegedi M; Kaló Z
Orphanet J Rare Dis; 2016 Jun; 11(1):72. PubMed ID: 27259284
[TBL] [Abstract][Full Text] [Related]
7. Health technology assessment of medical devices: What is different? An overview of three European projects.
Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
[TBL] [Abstract][Full Text] [Related]
8. Assessment of significant benefit for orphan medicinal products by European regulators may support subsequent relative effectiveness assessments by health technology assessment organizations.
Vreman RA; de Ruijter AS; Zawada A; Tafuri G; Stoyanova-Beninska V; O'Connor D; Naumann-Winter F; Wolter F; Mantel-Teeuwisse AK; Leufkens HGM; Sidiropoulos I; Larsson K; Goettsch WG
Drug Discov Today; 2020 Jul; 25(7):1223-1231. PubMed ID: 32344040
[TBL] [Abstract][Full Text] [Related]
9. Comparing access to orphan medicinal products in Europe.
Zamora B; Maignen F; O'Neill P; Mestre-Ferrandiz J; Garau M
Orphanet J Rare Dis; 2019 May; 14(1):95. PubMed ID: 31053154
[TBL] [Abstract][Full Text] [Related]
10. Principles for consistent value assessment and sustainable funding of orphan drugs in Europe.
Gutierrez L; Patris J; Hutchings A; Cowell W
Orphanet J Rare Dis; 2015 May; 10():53. PubMed ID: 25935555
[TBL] [Abstract][Full Text] [Related]
11. Developing an evidence-based methodological framework to systematically compare HTA coverage decisions: A mixed methods study.
Nicod E; Kanavos P
Health Policy; 2016 Jan; 120(1):35-45. PubMed ID: 26723201
[TBL] [Abstract][Full Text] [Related]
12. The European challenges of funding orphan medicinal products.
Szegedi M; Zelei T; Arickx F; Bucsics A; Cohn-Zanchetta E; Fürst J; Kamusheva M; Kawalec P; Petrova G; Slaby J; Stawowczyk E; Vocelka M; Zechmeister-Koss I; Kaló Z; Molnár MJ
Orphanet J Rare Dis; 2018 Nov; 13(1):184. PubMed ID: 30396361
[TBL] [Abstract][Full Text] [Related]
13. Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England.
Ten Ham RMT; Frederix GWJ; Wu O; Goettsch W; Leufkens HGM; Klungel OH; Hoekman J
Value Health; 2022 Mar; 25(3):390-399. PubMed ID: 35227451
[TBL] [Abstract][Full Text] [Related]
14. Recommendations from the European Working Group for Value Assessment and Funding Processes in Rare Diseases (ORPH-VAL).
Annemans L; Aymé S; Le Cam Y; Facey K; Gunther P; Nicod E; Reni M; Roux JL; Schlander M; Taylor D; Tomino C; Torrent-Farnell J; Upadhyaya S; Hutchings A; Le Dez L
Orphanet J Rare Dis; 2017 Mar; 12(1):50. PubMed ID: 28283046
[TBL] [Abstract][Full Text] [Related]
15. Market access for medicines treating rare diseases: Association between specialised processes for orphan medicines and funding recommendations.
Fontrier AM
Soc Sci Med; 2022 Aug; 306():115119. PubMed ID: 35700552
[TBL] [Abstract][Full Text] [Related]
16. Health technology assessment: research trends and future priorities in Europe.
Nielsen CP; Funch TM; Kristensen FB
J Health Serv Res Policy; 2011 Jul; 16 Suppl 2():6-15. PubMed ID: 21737525
[TBL] [Abstract][Full Text] [Related]
17. The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe.
Kawalec P; Sagan A; Pilc A
Orphanet J Rare Dis; 2016 Sep; 11(1):122. PubMed ID: 27600717
[TBL] [Abstract][Full Text] [Related]
18. Assessing the economic challenges posed by orphan drugs.
Drummond MF; Wilson DA; Kanavos P; Ubel P; Rovira J
Int J Technol Assess Health Care; 2007; 23(1):36-42. PubMed ID: 17234015
[TBL] [Abstract][Full Text] [Related]
19. Health Technology Assessment (HTA) Case Studies: Factors Influencing Divergent HTA Reimbursement Recommendations in Australia, Canada, England, and Scotland.
Allen N; Walker SR; Liberti L; Salek S
Value Health; 2017 Mar; 20(3):320-328. PubMed ID: 28292476
[TBL] [Abstract][Full Text] [Related]
20. Challenges in Research and Health Technology Assessment of Rare Disease Technologies: Report of the ISPOR Rare Disease Special Interest Group.
Nestler-Parr S; Korchagina D; Toumi M; Pashos CL; Blanchette C; Molsen E; Morel T; Simoens S; Kaló Z; Gatermann R; Redekop W
Value Health; 2018 May; 21(5):493-500. PubMed ID: 29753344
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
